Doctors Note Logo

Published on: 9/23/2026

What are RSV vaccine side effects in adults over 75?

Most adults over 75 who receive an RSV vaccine (Arexvy, Abrysvo, or mResvia) experience only mild, short-lived reactions such as injection site pain, fatigue, muscle aches, headache, joint pain, and sometimes low-grade fever, typically resolving within one to three days. Less common but more serious concerns include Guillain-Barré syndrome, reported at roughly 1 to 2 cases per million doses, along with rare allergic reactions and atrial fibrillation signals seen in clinical trials. Older age, frailty, existing heart or lung conditions, and other same-day vaccinations can all influence how strongly side effects are felt. There are several important factors to weigh, including timing, revaccination guidance, and which symptoms warrant urgent care, so see below to understand more.

If you are already feeling unwell after a vaccine or unsure whether your symptoms are a normal reaction or something that needs attention, a free, instant, online symptom check can help you sort typical post-vaccine effects from warning signs and point you toward the right next step in minutes.

Last reviewed for medical accuracy: 09/23/2026

answer background

Explanation

Understanding RSV and the Importance of Vaccination in Adults Over 75

Respiratory Syncytial Virus (RSV) is a common respiratory virus that causes mild, cold-like symptoms in most people. However, adults over 75 face a higher risk of severe illness, hospitalization, and complications. In response, health authorities in the U.S. have approved RSV vaccines specifically designed for older adults. As with any vaccine, it’s helpful to know what to expect. Below, we explore the rsv vaccine side effects over 75 — what’s typical, what’s uncommon, and when to seek medical advice.


Common Side Effects in Adults Over 75

Most people aged 75 and older tolerate the RSV vaccine well. The side effects generally mirror those seen with other adult vaccines, like the flu shot or COVID-19 booster. Common, mild-to-moderate side effects include:

  • Pain, redness or swelling at the injection site
  • Muscle aches or joint pain
  • Headache
  • Fatigue or mild tiredness
  • Low-grade fever (up to 100.4°F or 38°C)
  • Chills

These reactions usually develop within 24–48 hours of vaccination and resolve on their own within one to three days. They signal that your immune system is responding and building protection against RSV.


Less Common or Transient Reactions

In addition to the typical discomfort around the arm or mild flu-like symptoms, some adults over 75 may experience:

  • Mild nausea or upset stomach
  • Dizziness or lightheadedness (especially if standing up quickly)
  • Sweating
  • Mild swelling of nearby lymph nodes (such as under the arm)

These side effects are generally short-lived. Drinking plenty of water, resting, and using a cool compress at the injection site can help ease discomfort.


Rare but Serious Side Effects

Serious side effects from the RSV vaccine in older adults are very rare. However, it’s important to recognize them and seek prompt medical attention if they occur. Watch for:

  • Hives, severe rash or itching
  • Swelling of the face, lips, tongue or throat
  • Difficulty breathing or wheezing
  • Rapid heartbeat or palpitations
  • Dizziness that doesn’t go away or fainting
  • High fever (above 102°F or 38.9°C) lasting more than 48 hours

If you or a caregiver notice any of these symptoms after vaccination, call emergency services or go to the nearest emergency department right away. These may be signs of a severe allergic reaction (anaphylaxis) or other serious conditions requiring immediate care.


Why Side Effects May Differ in Those Over 75

Several factors can influence how older adults experience vaccine side effects:

  1. Immune System Changes
    As we age, our immune system responses can become less predictable. Some adults may notice fewer side effects because their immune system reacts more mildly. Others may feel stronger reactions as the body works to build protection.

  2. Underlying Health Conditions
    Chronic conditions like heart disease, diabetes or lung disease can affect how you feel after any vaccination. Always discuss your medical history with your healthcare provider before getting the RSV vaccine.

  3. Medications
    Certain medicines, such as blood thinners or immunosuppressants, may alter vaccine responses or interact with side effects like bruising at the injection site.


Managing Mild to Moderate Side Effects

If you experience common post-vaccine symptoms, here are some practical tips:

  • Apply a cool, damp cloth to the injection site to reduce soreness and swelling.
  • Move and stretch the arm gently to maintain circulation and decrease stiffness.
  • Stay hydrated by drinking water, herbal tea or clear broth.
  • Take over-the-counter pain relievers (acetaminophen or ibuprofen) if approved by your doctor.
  • Rest when you feel tired—your body is busy building protection.

Document your symptoms: note what you felt, when it started, and how long it lasted. This information can be helpful if you discuss your experience with a healthcare provider.


When to Seek Medical Advice

Even though most rsv vaccine side effects over 75 are mild, you should contact your doctor if you experience:

  • Side effects that worry you or don’t improve after 72 hours
  • Fever above 101°F (38.3°C) that lasts more than two days
  • Unusual bleeding or bruising around the injection site
  • Prolonged dizziness, confusion or severe headache
  • Any symptom that seems out of the ordinary for you

For non-urgent concerns or to learn more about your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. This tool can help you decide whether to seek in-person care.


Balancing Benefits and Risks

Vaccination remains one of the most effective ways to reduce severe RSV infections, hospitalizations and complications in older adults. While rsv vaccine side effects over 75 can be uncomfortable, they are typically brief and manageable. By preventing serious RSV illness—such as pneumonia or exacerbations of chronic lung disease—the vaccine’s benefits far outweigh the risks of side effects for most healthy adults.


Talking with Your Healthcare Provider

Before receiving the RSV vaccine, discuss the following with your doctor:

  • Your full medical history, including chronic conditions and medications
  • Any previous vaccine reactions you’ve had
  • Your current health status (recent infections, medications, etc.)
  • Possible interactions with other vaccines (flu, COVID-19 boosters)

This conversation will help your provider determine the best timing for vaccination and prepare strategies to manage any side effects.


Summary of Key Points

  • Adults over 75 are at higher risk for severe RSV illness; vaccination is strongly recommended.
  • Common side effects include mild pain at the injection site, fatigue, headache and low-grade fever.
  • Less common reactions may involve nausea, dizziness or lymph node swelling; these typically resolve in 1–3 days.
  • Serious side effects (allergic reactions, high fever, severe dizziness) are rare but require immediate medical attention.
  • Manage mild symptoms with rest, hydration, cool compresses and approved pain relievers.
  • Track your symptoms and reach out to your doctor if anything worsens or persists.
  • For non-urgent guidance, try a free, online symptom check, using the doctor approved Ubie Symptom Checker.

Final Reminder

While rsv vaccine side effects over 75 are generally mild and short-lived, every individual is unique. If you notice any concerning or life-threatening symptoms after vaccination, do not hesitate to speak to a doctor or call emergency services. Your health and peace of mind are the top priority.

(References)

  • * Qiu X, Xu S, Lu Y, Luo Z, Yan Y, Wang C, Ji J. Development of mRNA vaccines against respiratory syncytial virus (RSV). Cytokine Growth Factor Rev. 2022 Dec;68:37-53. doi: 10.1016/j.cytogfr.2022.10.001. Epub 2022 Oct 13. PMID: 36280532.

  • * Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrøm V, AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. PMID: 36791160.

  • * Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur C, Doreski PA, Ilangovan K, Rämet M, Fukushima Y, Hussen N, Bont LJ, Cardona J, DeHaan E, Castillo Villa G, Ingilizova M, Eiras D, Mikati T, Shah RN, Schneider K, Cooper D, Koury K, Lino MM, Anderson AS, Jansen KU, Swanson KA, Gurtman A, Gruber WC, Schmoele-Thoma B, RENOIR Clinical Trial Group. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med. 2023 Apr 20;388(16):1465-1477. doi: 10.1056/NEJMoa2213836. Epub 2023 Apr 5. PMID: 37018468.

  • * Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, Baker J, Pérez Marc G, Radley D, Shittu E, Glanternik J, Snaggs H, Baber J, Zachariah P, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Duron Padilla M, Richmond PC, Koury K, Schneider K, Kalinina EV, Cooper D, Jansen KU, Anderson AS, Swanson KA, Gruber WC, Gurtman A, MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023 Apr 20;388(16):1451-1464. doi: 10.1056/NEJMoa2216480. Epub 2023 Apr 5. PMID: 37018474.

  • * Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrøm V, Olivier A, Van der Wielen M, Descamps D, AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PMID: 38253338; PMCID: PMC11175669.

  • * Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NA, Sturkenboom MC, Wildenbeest JG, Bloemenkamp KW. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024 May 2;5(5):CD015134. doi: 10.1002/14651858.CD015134.pub2. Epub 2024 May 2. PMID: 38695784; PMCID: PMC11064886.

  • * Roman F, Burny W, Ceregido MA, Laupèze B, Temmerman ST, Warter L, Coccia M. Adjuvant system AS01: from mode of action to effective vaccines. Expert Rev Vaccines. 2024 Jan-Dec;23(1):715-729. doi: 10.1080/14760584.2024.2382725. Epub 2024 Aug 5. PMID: 39042099.

  • * Simões EAF, Pahud BA, Madhi SA, Kampmann B, Shittu E, Radley D, Llapur C, Baker J, Pérez Marc G, Barnabas SL, Fausett M, Adam T, Perreras N, Van Houten MA, Kantele A, Huang LM, Bont LJ, Otsuki T, Vargas SL, Gullam J, Tapiero B, Stein RT, Polack FP, Zar HJ, Staerke NB, Padilla MD, Richmond PC, Sarwar UN, Baber J, Koury K, Lino MM, Kalinina EV, Li W, Cooper D, Anderson AS, Swanson KA, Gurtman A, Munjal I, MATISSE (Maternal Immunization Study for Safety and Efficacy) Clinical Trial Group. Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 1;145(2):157-167. doi: 10.1097/AOG.0000000000005816. Epub 2025 Jan 2. PMID: 39746212; PMCID: PMC11731064.

  • * Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother. 2025;13:25151355241310601. doi: 10.1177/25151355241310601. Epub 2025 Jan 10. PMID: 39802673; PMCID: PMC11724408.

  • * Scott J, Abers MS, Marwah HK, McCann NC, Meyerowitz EA, Richterman A, Fleming DF, Holmes EJ, Moat LE, Redepenning SG, Smith EA, Stoddart CJ, Sundaram ME, Ulrich AK, Alba C, Anderson CJ, Arpey MK, Borre E, Ladines-Lim J, Mehr AJ, Rich K, Watts C, Basta NE, Jarolimova J, Walensky RP, Dugdale CM. Updated Evidence for Covid-19, RSV, and Influenza Vaccines for 2025-2026. N Engl J Med. 2025 Dec 4;393(22):2221-2242. doi: 10.1056/NEJMsa2514268. Epub 2025 Oct 29. PMID: 41160817.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.